X

Trial Profile

A Randomized Controlled Study of BAY 43-9006 [sorafenib] in Combination With Doxorubicin Versus Doxorubicin in Patients With Advanced Hepatocellular Carcinoma.

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 05 Sep 2019

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Sorafenib (Primary) ; Doxorubicin
Indications Liver cancer
Focus Therapeutic Use
Sponsors Bayer

Most Recent Events

12 Jul 2011 Additional trial location ( United Kingdom) identified as reported by EudraCT.
12 Jul 2011 New source identified and integrated (European Clinical Trials Database).
17 Nov 2010 Results published in the the Journal of the American Medical Association

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com